8 hours ago
1
miroslav110/iStock via Getty Images
ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical trial designed to test its FDA-approved Iluvien intravitreal implant against aflibercept, an eye care therapy marketed by Regeneron (
English (US) ·